Parodontax Complete Protection

PreclinicalSmall molecule

Parodontax Complete Protection is one of 3 small molecule programs targeting Dental Plaque. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Dental PlaqueCompleted

Dental PlaquePreclinical

Completed

Competition

Competitive Landscape

2 competitors in Dental Plaque

#DrugCompanyPhaseTrials

Colgate Cavity Protection

GSK

Preclinical

1 2

Test Dentifrice

HHALEON

Preclinical

2 3

Parodontax Complete Protection

HHALEON

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Dental Plaque1 trial

A 24-Week, Randomised, Controlled, Examiner-blind, Clinical Study to Evaluate the Efficacy of an Experimental Stannous Fluoride Dentifrice in Improving Gingival Health and Reducing Plaque Accumulation

Completed·HHALEON·Preclinical·NCT07255040·284 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Parodontax Complete Protection. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Parodontax Complete Protection compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Parodontax Complete Protection. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — HALEON company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: HHALEON

Parodontax Complete Protection

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Dental Plaque1 trial

References

Drug Info

Quick Facts

Related News